Advertisement

Drugs

, Volume 79, Issue 17, pp 1849–1866 | Cite as

Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer

  • Vassilis Aggelis
  • Stephen R. D. JohnstonEmail author
Review Article

Abstract

Approximately 70% of breast cancers are estrogen-receptor positive. Tamoxifen and aromatase inhibitors have been the mainstay of endocrine therapy and have improved breast cancer survival. However, a large number of patients experience disease recurrence either during or following completion of endocrine therapy. Recent improvements in our understanding of the various mechanisms underlying the development of endocrine resistance have led to a dramatic change in the landscape of current endocrine treatment with the introduction of new drugs targeting molecular pathways involved in endocrine resistance. Over the past years we have witnessed the use of combination endocrine therapy with mammalian target of rapamycin antagonists, whilst most recently the introduction of cyclin-dependent kinase 4/6 inhibitors has significantly improved response to endocrine therapy. Whilst not a formal systematic review, this article will provide historical background and summarise key clinical trials and current strategies in both first-line and second-line endocrine therapy.

Notes

Compliance with Ethical Standards

Funding

No external funding was used in preparation of this manuscript.

Conflict of interest

Dr. Vassilis Aggelis has received a speaker honorarium from Pfizer. Prof. Stephen Johnston has received consultancy/speaker honorarium from Pfizer, Eli Lilly, Eisai, AstraZeneca, Novartis and Puma Biotechnology, and research funding to the Institution from Pfizer, Puma Biotechnology and AstraZeneca.

References

  1. 1.
    Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat. 2002;76(1):27–36.PubMedGoogle Scholar
  2. 2.
    Nishimura R, Osako T, Okumura Y, Tashima R, Toyozumi Y, Arima N. Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis. World J Surg Oncol. 2011.  https://doi.org/10.1186/1477-7819-9-131.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, et al. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol. 2017;28(1):16–33.PubMedGoogle Scholar
  4. 4.
    Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer. 2004;11:643–58.PubMedGoogle Scholar
  5. 5.
    Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer. 2002;2(2):101–12.PubMedGoogle Scholar
  6. 6.
    Johnston SRD. Enhancing endocrine therapy for hormone receptor-positive advanced breast cancer: cotargeting signaling pathways. J Natl Cancer Inst. 2015;107.  https://doi.org/10.1093/jnci/djv212.PubMedGoogle Scholar
  7. 7.
    Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62(1):233–47.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol. 2011;29(33):4452–61.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Stephen RL, Shaw LE, Larsen C, Corcoran D, Darbre PD. Insulin-like growth factor receptor levels are regulated by cell density and by long term estrogen deprivation in MCF7 human breast cancer cells. J Biol Chem. 2001;276(43):40080–6.PubMedGoogle Scholar
  10. 10.
    Shim WS, Conaway M, Masamura S, Yue W, Wang JP, Kumar R, et al. Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology. 2000;141(1):396–405.PubMedGoogle Scholar
  11. 11.
    Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α: a new model for anti-estrogen resistance. J Biol Chem. 2001;276(13):9817–24.PubMedGoogle Scholar
  12. 12.
    Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol. 2011;29:4452–61.PubMedPubMedCentralGoogle Scholar
  13. 13.
    DeGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clin Cancer Res. 2004;10(23):8059–67.PubMedGoogle Scholar
  14. 14.
    Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O’Reilly T, Evans DB, et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res. 2005;11(14):5319–28. http://www.ncbi.nlm.nih.gov/pubmed/16033851.PubMedGoogle Scholar
  15. 15.
    Kurokawa H, Lenferink AEG, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT, et al. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res. 2000;60(20):5887–94.PubMedGoogle Scholar
  16. 16.
    Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 2005;23:7721–35.PubMedGoogle Scholar
  17. 17.
    Abdel-Hafiz H. Epigenetic mechanisms of tamoxifen resistance in luminal breast cancer. Diseases. 2017;5(3):16.  https://doi.org/10.3390/diseases5030016.CrossRefPubMedCentralGoogle Scholar
  18. 18.
    Milani A, Geuna E, Mittica G, Valabrega G. Overcoming endocrine resistance in metastatic breast cancer: current evidence and future directions. World J Clin Oncol. 2014;5(5):990–1001.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Murphy CG, Dickler MN. Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies. Endocr Relat Cancer. 2016;23:R337–52.PubMedGoogle Scholar
  20. 20.
    Lange CA, Yee D. Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer. Endocr Relat Cancer. 2011.  https://doi.org/10.1530/erc-11-0112.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Cole MP, Jones CTA, Todd IDH. A new anti-oestrogenic agent in late breast cancer an early clinical appraisal of ICI46474. Br J Cancer. 1971;25(2):270–5.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thurlimann B, von Euler M, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer. 2001;92(9):2247–58.PubMedGoogle Scholar
  23. 23.
    Bonneterre J, Thürlimann B, Robertson JFR, Krzakowski M, Mauriac L, Koralewski P, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol. 2000;18(22):3748–57.PubMedGoogle Scholar
  24. 24.
    Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med. 2003;348(24):2431–42.PubMedGoogle Scholar
  25. 25.
    Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol. 2000;18(22):3758–67.Google Scholar
  26. 26.
    Paridaens RJ, Dirix LY, Beex LV, Nooij M, Cameron DA, Cufer T, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol. 2008;26(30):4883–90.  https://doi.org/10.1200/jco.2007.14.4659(Epub 2008 Sep 15).CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Mouridsen H, Gershanovich M, Sun Y, Pérez-Carrión R, Boni C, Monnier A, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003;21(11):2101–9.PubMedGoogle Scholar
  28. 28.
    Walker GA, Xenophontos M, Chen LC, Cheung KL. Long-term efficacy and safety of exemestane in the treatment of breast cancer. Patient Prefer Adher. 2013;7:245–58.Google Scholar
  29. 29.
    Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. 2008;26(10):1664–70. http://www.ncbi.nlm.nih.gov/pubmed/18316794.PubMedGoogle Scholar
  30. 30.
    Johnston SRD, Kilburn LS, Ellis P, Dodwell D, Cameron D, Hayward L, et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr. Lancet Oncol. 2013;14(10):989–98.PubMedGoogle Scholar
  31. 31.
    Osborne CK, Wakeling A, Nicholson RI. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer. 2004;90:S2–6.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Howell A, Robertson JFR, Abram P, Lichinitser MR, Elledge R, Bajetta E, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol. 2004;22(9):1605–13. http://www.ncbi.nlm.nih.gov/pubmed/15117982.PubMedGoogle Scholar
  33. 33.
    Bergh J, Jönsson PE, Lidbrink EK, Trudeau M, Eiermann W, Brattström D, et al. FACT: An open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol. 2012;30(16):1919–25.PubMedGoogle Scholar
  34. 34.
    Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Livingston RB, Gabriel N. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med. 2012;367:435–44.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Robertson JFR, Nicholson RI, Bundred NJ, Anderson E, Rayter Z, Dowsett M, et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res. 2001;61(18):6739–46. http://www.ncbi.nlm.nih.gov/pubmed/11559545.
  36. 36.
    Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010;28(30):4594–600.PubMedGoogle Scholar
  37. 37.
    Robertson JFR, Lindemann JPO, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study. Breast Cancer Res Treat. 2012;136(2):503–11. http://link.springer.com/10.1007/s10549-012-2192-4.PubMedGoogle Scholar
  38. 38.
    Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016;388(10063):2997–3005. http://linkinghub.elsevier.com/retrieve/pii/S0140673616323893.Google Scholar
  39. 39.
    Osborne CK, Neven P, Dirix LY, Mackey JR, Robert J, Underhill C, et al. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res. 2011;17(5):1147–59.  https://doi.org/10.1158/1078-0432.ccr-10-1869(Epub 2011 Jan 10).CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Cristofanilli M, Schiff R V. Exploratory subset analysis according to prior endocrine treatment of two randomized phase II trials comparing gefitinib (G) with placebo (P) in combination with tamoxifen (T) or anastrozole (A) in hormone receptor-positive (HR+) metastatic breast cancer. J Clin Oncol. 2009;27(15 Supp) (Abstract 104).Google Scholar
  41. 41.
    Johnston S, Basik M, Hegg R, Lausoontornsiri W, Grzeda L, Clemons M, et al. Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: phase II randomized study in women with endocrine-therapy-naive advanced breast cancer. Breast Cancer Res Treat. 2016;160(1):91–9.PubMedGoogle Scholar
  42. 42.
    Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 2010;70(5):2085–94.PubMedPubMedCentralGoogle Scholar
  43. 43.
    Robertson JFR, Ferrero JM, Bourgeois H, Kennecke H, de Boer RH, Jacot W, et al. Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial. Lancet Oncol. 2013;14:228–35.PubMedGoogle Scholar
  44. 44.
    Study of MEDI-573 Plus standard endocrine therapy for women with hormone-sensitive metastatic breast cancer. https://clinicaltrials.gov/ct2/show/results/NCT01446159. Cited 14 Jan 2019.
  45. 45.
    Musolino A, Campone M, Neven P, Denduluri N, Barrios CH, Cortes J, et al. Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2-breast cancer that had progressed during or after prior endocrine therapy. Breast Cancer Res. 2017;19(1).  https://doi.org/10.1186/s13058-017-0807-8.
  46. 46.
    Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: Results from the randomized phase III TAnDEM study. J Clin Oncol. 2009;27(33):5529–37.PubMedGoogle Scholar
  47. 47.
    Huober J, Fasching PA, Barsoum M, Petruzelka L, Wallwiener D, Thomssen C, et al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - Results of the eLEcTRA trial. Breast. 2012;21(1):27–33.PubMedGoogle Scholar
  48. 48.
    Johnston S, Pippen J, Pivot X, Lichinitser M, Sadeghi S, Dieras V, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor—positive metastatic breast cancer. J Clin Oncol. 2009;27(33):5538–46.PubMedGoogle Scholar
  49. 49.
    Schwartzberg LS, Franco SX, Florance A, O’Rourke L, Maltzman J, Johnston S. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist. 2010;15(2):122–9.  https://doi.org/10.1634/theoncologist.2009-0240(Epub 2010 Feb 15).CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Ben-Baruch NE, Bose R, Kavuri SM, Ma CX, Ellis MJ. HER2-mutated breast cancer responds to treatment with single-agent neratinib, a second-generation HER2/EGFR tyrosine kinase inhibitor. JNCCN J Natl Compr Cancer Netw. 2015;13(9):1061–4.Google Scholar
  51. 51.
    Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77.  https://doi.org/10.1186/bcr2419.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Thangavel C, Dean JL, Ertel A, Knudsen KE, Aldaz CM, Witkiewicz AK, et al. Therapeutically activating RB: Reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer. 2011;18(3):333–45.PubMedPubMedCentralGoogle Scholar
  53. 53.
    Finn RS, Martin M, Rugo HS, Jones S, Im S-A, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–36. http://www.nejm.org/doi/10.1056/NEJMoa1607303.PubMedGoogle Scholar
  54. 54.
    Rugo HS, Finn RS, Diéras V, Ettl J, Lipatov O, Joy AA, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat. 2019;5:1–19.  https://doi.org/10.1200/jgo.18.00173.CrossRefGoogle Scholar
  55. 55.
    Tripathy D, Bardia A, Sellers WR. Ribociclib (LEE011): mechanism of action and clinical impact of this selective cyclin-dependent kinase 4 / 6 inhibitor in various solid tumors. Clin Cancer Res. 2017;1–29. http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-16-3157%5Cnhttp://www.ncbi.nlm.nih.gov/pubmed/28351928.
  56. 56.
    Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–48. http://www.nejm.org/doi/10.1056/NEJMoa1609709.
  57. 57.
    Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2−), advanced breast cancer (ABC). J Clin Oncol. 2017;35(15_suppl):1038. http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.1038.Google Scholar
  58. 58.
    Im SA, Bardia A, Harbeck N, Colleoni M, Franke F, Chow L, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381:307–16.PubMedGoogle Scholar
  59. 59.
    Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Del Prado M, Lallena MJ, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: In-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Investig New Drugs. 2014;32(5):825–37.Google Scholar
  60. 60.
    Dickler MN, Tolaney SM, Rugo HS, Cortés J, Diéras V, Patt D, et al. MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR(+)/HER2(−) metastatic breast cancer. Clin Cancer Res. 2017;23(17):5218–24.  https://doi.org/10.1158/1078-0432.ccr-17-0754. (Epub 2017 May 22). http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-17-0754%5Cnhttp://www.ncbi.nlm.nih.gov/pubmed/28533223.PubMedPubMedCentralGoogle Scholar
  61. 61.
    Johnston S, Martin M, Di Leo A, Im S-A, Awada A, Forrester T, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019;5:5.  https://doi.org/10.1038/s41523-018-0097-zeCollection2019.
  62. 62.
    Beeram M, Tan QTN, Tekmal RR, Russell D, Middleton A, deGraffenried LA. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol. 2007;18(8):1323–8.PubMedGoogle Scholar
  63. 63.
    Yu K, Toral-Barza L, Discafani C, Zhang WG, Skotnicki J, Frost P, et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer. 2001;8:249–58.PubMedGoogle Scholar
  64. 64.
    Wolff AC, Lazar AA, Bondarenko I, Garin AM, Brincat S, Chow L, et al. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol. 2013;31(2):195–202. http://www.ncbi.nlm.nih.gov/pubmed/23233719%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC3532391.PubMedGoogle Scholar
  65. 65.
    Johnston SRD. Are we missing the mTOR target in breast cancer? Breast Cancer Res Treat. 2011;128:607–11.PubMedGoogle Scholar
  66. 66.
    MacAskill EJ, Bartlett JMS, Sabine VS, Faratian D, Renshaw L, White S, et al. The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study. Breast Cancer Res Treat. 2011;128(3):725–34.PubMedGoogle Scholar
  67. 67.
    Gradishar WJ, Bachelot TD, Saletan S, Graham AM, Liedke PER, Azevedo SJ, et al. BOLERO-4: Multicenter, open-label, phase II study of everolimus plus letrozole as first-line therapy in OESTROGEN RECEPTOR-POSITIVE, HER2- metastatic breast cancer. J Clin Oncol. 2013;31(suppl):abstr TPS661. http://meetinglibrary.asco.org/content/111942-132.
  68. 68.
    Steger GG, Bartsch R, Wenzel C, Pluschnig U, Hussian D, Sevelda U, et al. Fulvestrant (‘Faslodex’) in pre-treated patients with advanced breast cancer: a single-centre experience. Eur J Cancer. 2005;41(17):2655–61.PubMedGoogle Scholar
  69. 69.
    Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol. 2012;30(22):2718–24.PubMedGoogle Scholar
  70. 70.
    Yardley DA, Noguchi S, Pritchard KI, Burris HA, Baselga J, Gnant M, et al. Everolimus plus exemestane in postmenopausal patients with HR+breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013;30(10):870–84.PubMedPubMedCentralGoogle Scholar
  71. 71.
    Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, et al. Everolimus plus exemestane for hormone- receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol. 2014;25:2357–62.PubMedPubMedCentralGoogle Scholar
  72. 72.
    Hortobagyi GN, Chen D, Piccart M, Rugo HS, Burris HA, Pritchard KI, et al. Correlative analysis of genetic alterations and everolimus benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from BOLERO-2. J Clin Oncol. 2016;34(5):419–26.PubMedGoogle Scholar
  73. 73.
    Massacesi C, di Tomaso E, Urban P, Germa C, Quadt C, Trandafir L, et al. PI3K inhibitors as new cancer therapeutics: implications for clinical trial design. OncoTargets Ther. 2016;9:203–10.Google Scholar
  74. 74.
    Baselga J, Im S-A, Iwata H, Cortés J, De Laurentiis M, Jiang Z, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(7):904–16. http://linkinghub.elsevier.com/retrieve/pii/S1470204517303765.
  75. 75.
    Di Leo A, Johnston S, Lee KS, Ciruelos E, Lønning PE, Janni W, et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19(1):87–100.PubMedGoogle Scholar
  76. 76.
    Krop IE, Mayer IA, Ganju V, Dickler M, Johnston S, Morales S, et al. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016;17(6):811–21.PubMedPubMedCentralGoogle Scholar
  77. 77.
    André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380(20):1929–40.  https://doi.org/10.1056/nejmoa1813904.CrossRefPubMedGoogle Scholar
  78. 78.
    Baselga J, Dent SF, Cortes J et al: Phase III study of taselisib (GDC-0032) plus fulvestrant versus fulvestrant in patients with estrogen receptor-positive, PIK3CA-mutant, locally advanced or metastatic breast cancer: primary analysis from SANDPIPER. 2018 ASCO Annu Meet Abstr LBA1006.Google Scholar
  79. 79.
    Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase. Lancet Oncol. 2016;17(4):425–39.PubMedGoogle Scholar
  80. 80.
    Turner NC, Slamon DJ, Ro J, Bondarenko I, Im S-A, Masuda N, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379(20):1926–36.  https://doi.org/10.1056/nejmoa1810527(Epub 2018 Oct 20).CrossRefPubMedGoogle Scholar
  81. 81.
    Sledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2-advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875–84.PubMedGoogle Scholar
  82. 82.
    Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465–72.  https://doi.org/10.1200/jco.2018.78.9909(Epub 2018 Jun 3).CrossRefPubMedGoogle Scholar
  83. 83.
    Raha P, Thomas S, Thurn KT, Park J, Munster PN. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen resistant breast cancer models, by reversing Bcl-2 overexpression. Breast Cancer Res. 2015;17(1):533. http://www.ncbi.nlm.nih.gov/pubmed/25848915.
  84. 84.
    Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM, et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromata. J Clin Oncol. 2013;31(17):2128–35.PubMedPubMedCentralGoogle Scholar
  85. 85.
    Yeruva SLH, Zhao F, Miller KD, Tevaarwerk AJ, Wagner LI, Gray RJ, et al. E2112: Randomized phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. NPJ Breast Cancer. 2018;11(4):1.  https://doi.org/10.1038/s41523-017-0053-3.CrossRefGoogle Scholar
  86. 86.
    Qingyuan Zhang, Tao Wang, Cuizhi Geng, Yue Zhang, Jinwen Zhang, Zhi-Qiang Ning ZJ. Pilot trial of chidamide, an oral histone deacetylase (HDAC) inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer. 2018. http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e12543. Cited 15 Jan 2019.
  87. 87.
    Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016;17(6):717–26.PubMedGoogle Scholar
  88. 88.
    Dirix L, Takacs I, Nikolinakos P, Jerusalem G, Arkenau H-T, Hamilton E, et al. Abstract S1-04: Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase Ib JAVELIN solid tumor trial. Cancer Res. 2016;76(4 Suppl):S1-04-S1-04. http://cancerres.aacrjournals.org/lookup/doi/10.1158/1538-7445.SABCS15-S1-04.
  89. 89.
    Di Leo A, O’Shaughnessy J, Sledge GWJ, Martin M, Lin Y, Frenzel M, et al. Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy. NPJ Breast Cancer. 2018;Google Scholar
  90. 90.
    Van Ommen-Nijhof A, Konings IR, Van Zeijl CJJ, Uyl-De Groot CA, Van Der Noort V, Jager A, et al. Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer—the SONIA study: Study protocol for a randomized controlled trial. BMC Cancer. 2018;18(1):1146.  https://doi.org/10.1186/s12885-018-4978-1.CrossRefPubMedPubMedCentralGoogle Scholar
  91. 91.
    Turner N, Swift C, Kilburn L, Garcia-Murillas I, Johnston S, Budzar A, et al. Abstract PD2-04: baseline circulating ESR1 mutation analysis in the randomised phase III EFECT study of fulvestrant versus exemestane in advanced hormone receptor positive breast cancer; 2019. https://cancerres.aacrjournals.org/content/79/4_Supplement/PD2-04.

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of MedicineRoyal Marsden NHS Foundation TrustLondonUK

Personalised recommendations